Concomitant use of clopidogrel and proton-pump inhibitor

A reality check

Subhash Banerjee, Ahmad Zankar, Rick Weideman, Bertis Little, Emmanouil S. Brilakis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

There are emerging reports supporting the fact that proton-pump inhibitors competitively inhibit the metabolism of clopidogrel to its active metabolite and diminish its clinical efficacy, especially in patients on long-term dual antiplatelet therapy. In this article, we examine the current evidence and provide interpretation of the results along with practical recommendations for healthcare providers.

Original languageEnglish (US)
Pages (from-to)121-125
Number of pages5
JournalInterventional Cardiology
Volume2
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

clopidogrel
Proton Pump Inhibitors
Health Personnel
Therapeutics

Keywords

  • cardiovascular outcome
  • clopidogrel
  • proton-pump inhibitor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Concomitant use of clopidogrel and proton-pump inhibitor : A reality check. / Banerjee, Subhash; Zankar, Ahmad; Weideman, Rick; Little, Bertis; Brilakis, Emmanouil S.

In: Interventional Cardiology, Vol. 2, No. 2, 04.2010, p. 121-125.

Research output: Contribution to journalArticle

Banerjee, Subhash ; Zankar, Ahmad ; Weideman, Rick ; Little, Bertis ; Brilakis, Emmanouil S. / Concomitant use of clopidogrel and proton-pump inhibitor : A reality check. In: Interventional Cardiology. 2010 ; Vol. 2, No. 2. pp. 121-125.
@article{f52b34f3d4e841ddb7d69476340e332d,
title = "Concomitant use of clopidogrel and proton-pump inhibitor: A reality check",
abstract = "There are emerging reports supporting the fact that proton-pump inhibitors competitively inhibit the metabolism of clopidogrel to its active metabolite and diminish its clinical efficacy, especially in patients on long-term dual antiplatelet therapy. In this article, we examine the current evidence and provide interpretation of the results along with practical recommendations for healthcare providers.",
keywords = "cardiovascular outcome, clopidogrel, proton-pump inhibitor",
author = "Subhash Banerjee and Ahmad Zankar and Rick Weideman and Bertis Little and Brilakis, {Emmanouil S.}",
year = "2010",
month = "4",
doi = "10.2217/ica.10.12",
language = "English (US)",
volume = "2",
pages = "121--125",
journal = "Interventional Cardiology (London)",
issn = "1755-5302",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Concomitant use of clopidogrel and proton-pump inhibitor

T2 - A reality check

AU - Banerjee, Subhash

AU - Zankar, Ahmad

AU - Weideman, Rick

AU - Little, Bertis

AU - Brilakis, Emmanouil S.

PY - 2010/4

Y1 - 2010/4

N2 - There are emerging reports supporting the fact that proton-pump inhibitors competitively inhibit the metabolism of clopidogrel to its active metabolite and diminish its clinical efficacy, especially in patients on long-term dual antiplatelet therapy. In this article, we examine the current evidence and provide interpretation of the results along with practical recommendations for healthcare providers.

AB - There are emerging reports supporting the fact that proton-pump inhibitors competitively inhibit the metabolism of clopidogrel to its active metabolite and diminish its clinical efficacy, especially in patients on long-term dual antiplatelet therapy. In this article, we examine the current evidence and provide interpretation of the results along with practical recommendations for healthcare providers.

KW - cardiovascular outcome

KW - clopidogrel

KW - proton-pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77954136399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954136399&partnerID=8YFLogxK

U2 - 10.2217/ica.10.12

DO - 10.2217/ica.10.12

M3 - Article

VL - 2

SP - 121

EP - 125

JO - Interventional Cardiology (London)

JF - Interventional Cardiology (London)

SN - 1755-5302

IS - 2

ER -